Sign inJoin waitlistJoin the waitlist

Emese Zsiros

2022-Present - Co-Leader of the Tumor Immunology and Immunotherapy Program in the CCSG · ROSWELL PARK CANCER INSTITUTE

Credentials: · · · · · · · ·

History

Tumor Immunology and Immunotherapy Program in the CCSG · ROSWELL PARK CANCER INSTITUTE
Present
Department of Gynecologic Oncology · ROSWELL PARK CANCER INSTITUTE
Present
ROSWELL PARK CANCER INSTITUTE
Present

Gynecologic Oncology
University of Pennsylvania
2011–2014
Obstetrics and Gynecology
McGaw Medical Center of Northwestern University
2007–2011
University of Debrecen Faculty of General Medicine
2001–2005
Biomedical Sciences, University of Debrecen

Research

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2021 · 587 citations
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
Journal of the National Comprehensive Cancer Network · 2022 · 346 citations
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
Journal of the National Comprehensive Cancer Network · 2019 · 213 citations

Brahm Segal
11 papers
JS
James Szender
10 papers · 10 as a fellow
SL
Shashikant Lele
8 papers
Peter Frederick
7 papers
Andrew Berchuck
6 papers · 1 as a resident
Gyorgy Paragh
6 papers
Kristen Starbuck
6 papers · 5 as a fellow
Heidi Gray
5 papers
Janos Tanyi
5 papers
Robert Edwards
5 papers
Angela Jain
4 papers
Ardeshir Hakam
4 papers

Grants

Targeting Complement to Enhance Antitumor Immunity and Control Malignant Effusions in Patients with Recurrent Epithelial Ovarian Cancer
National Cancer Institute · R01
Contact PI · $3.3M · Roswell Park Cancer Institute Corp
2022–2027
Network Lead Academic Participating Site Grant from the Roswell Park Cancer Institute
National Cancer Institute · UG1
PI · $437.6K · Roswell Park Cancer Institute Corp
2019–2026

Clinical trials

GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer
Principal investigator · Recruiting · Phase 1
Roswell Park Cancer Institute
2026–2030
An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study
Principal investigator · Recruiting
Roswell Park Cancer Institute
2025–2028
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Principal investigator · Recruiting · Phase 2
Roswell Park Cancer Institute
2024–2027
Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Principal investigator · Withdrawn · Phase 1, Phase 2
Roswell Park Cancer Institute
2023–2025